| oxaliplatin / Generic mfg. |
NCT00005035: Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI) | Head and Neck Cancer | | 03/04 | | |
NCT00005837: Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer |
|
|
| Completed | 2 | | US, Canada | oxaliplatin | Gynecologic Oncology Group, National Cancer Institute (NCI) | Cervical Cancer | | 06/04 | | |
| Terminated | 2 | 9 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Dana-Farber Cancer Institute, National Cancer Institute (NCI), Sanofi-Synthelabo | Head and Neck Cancer | 03/07 | 03/08 | | |
NCT00448552: Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer |
|
|
| Completed | 2 | 30 | US | capecitabine, oxaliplatin | University of Miami | Head and Neck Cancer | 04/07 | 06/08 | | |
NCT00503997: Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer |
|
|
| Completed | 2 | 42 | US | oxaliplatin, Eloxatin, pemetrexed disodium, Alimta | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Head and Neck Cancer | 06/09 | 06/10 | | |
NCT00184028: Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck |
|
|
| Terminated | 2 | 12 | US | Taxotere, Oxaliplatin | University of Southern California, Sanofi | Carcinoma of the Head and Neck | 07/09 | 07/10 | | |
NCT00557206: Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer |
|
|
| Terminated | 2 | 35 | US | Oxaliplatin and Docetaxel | Minneapolis Veterans Affairs Medical Center, Sanofi | Neoplasms, Head and Neck Neoplasms | 11/09 | 11/09 | | |
NCT00057863: Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer |
|
|
| Completed | 2 | 35 | US | Paclitaxel, Anzatax, TAX, Oxaliplatin | National Cancer Institute (NCI) | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer | 12/09 | 03/10 | | |
NCT00256308: Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer |
|
|
| Terminated | 2 | 6 | US | Oxaliplatin, Eloxatin, Radiation | University of California, Irvine, Sanofi | Head and Neck Cancer | 05/10 | 10/11 | | |
NCT01605305: Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer |
|
|
| Completed | 2 | 60 | RoW | FOLFOX6 | Fudan University | Esophageal Squamous Cell Carcinoma | 01/12 | 01/12 | | |
NCT00591149: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer |
|
|
| Terminated | 2 | 16 | US | Oxaliplatin, Eloxatin, Docetaxel, Taxotere, Cetuximab, Erbitux | University of Kansas Medical Center, Sanofi | Head and Neck Cancer, Carcinoma, Squamous | 04/12 | 04/12 | | |
NCT00093379: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer |
|
|
| Completed | 2 | 20 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Radiation Therapy (XRT), XRT, RT, Radiotherapy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Anal Cancer | 07/12 | 07/12 | | |
NCT00470184: Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer |
|
|
| Completed | 2 | 41 | US | capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy | Roswell Park Cancer Institute, National Comprehensive Cancer Network | Esophageal Cancer | 10/12 | | | |
NCT01178944: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 35 | US | Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX | Roswell Park Cancer Institute, National Cancer Institute (NCI), National Comprehensive Cancer Network | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma | 01/15 | 11/15 | | |
| Terminated | 2 | 105 | Europe | FU-CDDP, Fluoro-uracil+CisPlatin, LV5FU2-CDDP, Elvorin+Fluoro-uracil+CisPlatin, FOLFOX, Oxaliplatin+Fluoro-uracil+Elvorin, TPF, Docetaxel+CisPlatine+Fluoro-uracile, Best Supportive Care, antalgic treatment, nutritional support, ... | Centre Oscar Lambret, National Cancer Institute, France | Squamous Cell Carcinoma of Esophagus | 01/16 | 01/17 | | |
NCT00093652: Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer |
|
|
| Terminated | 1/2 | | US | gefitinib, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy | Roswell Park Cancer Institute | Esophageal Cancer | 05/06 | | | |
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Terminated | 1/2 | 9 | US | docetaxel, oxaliplatin, vandetanib, placebo | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 06/10 | | | |
|
